Two experimental drugs failed to prevent or slow mental decline in a study of people who are virtually destined to develop Alzheimer’s disease at a relatively young age because they inherited rare gene flaws.

The results announced Monday are another disappointment for the approach that scientists have focused on for years — trying to remove a harmful protein that builds up in the brains of people with Alzheimer’s, the leading cause of dementia.

“We actually don’t even know yet what the drugs did” in term of removing that protein because those results are still being analyzed, said study leader Dr. Randall Bateman at Washington University in St. Louis, Missouri.

But after five years on average, the main goal of the study was not met — people on either of the drugs scored about the same on thinking and memory tests as others given placebo treatments.

More than 5 million people in the United States and millions more worldwide have Alzheimer’s. Current drugs only temporarily ease symptoms and do not alter the course of the disease.

The study tested solanezumab by Eli Lilly & Co., and gantenerumab by Swiss drugmaker Roche and its U.S. subsidiary, Genentech. Both drugs gave disappointing results in some earlier studies, but the doses in this one ranged up to four to five times higher and researchers had hoped that would prove more effective.

The study was funded by the U.S. National Institute on Aging, the Alzheimer’s Association and some foundations.

It involved about 200 people in the United States, Europe and elsewhere with flaws in one of three genes.

“If you get one of these genetic mutations you’re almost guaranteed to get Alzheimer’s,” typically in your 30s, 40s or 50s, said Dr. Eric McDade, another study leader at Washington University.

People like this account for only about 1% of Alzheimer’s cases, but their brain changes and symptoms are similar to those who develop the disease at a later age. That gives a unique chance to test potential treatments.

“We know everyone will get sick and we know about what time that is” in their lives, Bateman said.

Most study participants already had signs of the harmful protein in their brain even if they were showing no symptoms when the study started.

The were given either a gantenerumab shot, an IV of solanezumab or fake versions of these treatments every four weeks. The drugs made no difference in a combination score of four memory and thinking tests compared to placebo treatments.

Side effects were not disclosed, but “there’s no evidence of any drug-related deaths in the trial,” McDade said.

Details will be given at a medical meeting in April.

Solanezumab is being tested in another study to see if it can slow memory loss in people with Alzheimer’s.

Gantenerumab also is being tested in two other large experiments that are expected to give results in two to three years.

It’s unclear whether the results will affect views on aducanumab, another experimental drug whose makers say it can remove the harmful protein and slow mental decline. Results on it have been mixed, and the companies have said they will seek federal approval for it soon. Cambridge, Massachusetts-based Biogen is developing it with a Japanese company, Eisai Co. Ltd.

Related Stories
‹
One on One: Dad and Alzheimer’s
D.G. Martin re-shares a column from 1998 about his family's relationship to Alzheimer's, and one's ability to recognize and face death.
UNC, Duke Establish Joint Alzheimer's Research Center with NIH Grant
UNC and Duke are teaming up to establish a joint Alzheimer’s Disease Research Center. One of 33, the UNC-Duke center plans to focus on how factors relating to the development of Alzheimer’s arise later contributing to racial, ethnic, and geographic disparities in developing dementia.
FDA Panel Reviews 1st New Alzheimer’s Drug in 2 Decades
One of the biggest drug decisions in decades is looming as U.S. regulators consider whether to approve the first medicine that’s claimed to slow mental decline from Alzheimer’s disease, the most common form of dementia. A panel of outside experts meets Friday to advise the Food and Drug Administration on aducanumab, a drug from Cambridge, […]
Orange County Launches "Dementia-Friendly" Initiative
The county is using a $900,000 grant to launch an initiative to help those living with dementia.
The Caring Corner, presented by ACORN: Memory Problems
What is mild forgetfulness? It’s a given that many of us will become more forgetful as we get older. It takes longer to learn new things, to find our glasses or car keys, to remember somebody’s name. These events, while disquieting, are not considered by doctors to be serious memory problems. You should confer with […]
The Caring Corner, presented by Acorn: End of Life Concerns
Thinking About the “Final Chapter”?  These Books May Help “Don’t send me flowers when I’m dead.  If you like me, send them while I’m alive.”   – Brian Clough With the immense popularity of Atul Gawande’s 2014 book Being Mortal, there’s been a surge of interest in learning about end-of-life concerns – and making informed decisions  […]
The Caring Corner, presented by Acorn: Arrest Rates for Elder Americans Are On the Rise
In the 1986 comedy, Tough Guys, ex-cons Burt Lancaster and Kirk Douglas, well into their 60’s after serving years in prison for train robbery, decide to rob one again.  For most older Americans, however, whose paths are crossing with law enforcement, it’s far from deliberate. In the decade ending in 2012 (the last year for […]
The Caring Corner, presented by Acorn: Why Does Dad ask me the same question again and again?
It can be one of the most frustrating aspects of having a loved one with dementia.  Dad will ask the same question repeatedly.  “What time are you picking me up?” You answer him, and three minutes later he asks it again.  “What time are you picking me up?”   You lose your temper. You say something […]
The Caring Corner: Can Chocolate Be a Cure for Dementia?
Can Chocolate Be a Cure for Dementia? Don’t you love it when something you love is also good for you?   That may just be the case with chocolate. A new pill released in the UK is made entirely out of chocolate.  It contains flavanols extracted from cocoa that lower cholesterol and improve blood flow.   Research […]
The Caring Corner: Will Medicare Pay for Home Care?
Will Medicare Pay for Home Care? So often we get calls from folks who ask if Medicare will pay for home care visits.  They had a friend who was recovering from hip surgery and nursing assistants came to her home, compliments of Medicare. While yes, Medicare will pay for home care visits, it only does […]
›